within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AB18_Molnupiravir;

model Molnupiravir
  extends Pharmacolibrary.Drugs.ATC.J.J05AB18;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>J05AB18</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Molnupiravir is an oral antiviral prodrug of the ribonucleoside analog N4-hydroxycytidine. It inhibits replication of SARS-CoV-2, the virus responsible for COVID-19. It is used for the treatment of mild to moderate COVID-19 in adults at risk of progressing to severe disease. It has received emergency use authorization in some regions.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers (median age 25-52 years) after oral administration, single dose, fasting state.</p><h4>References</h4><ol><li><p>Saravolatz, LD, et al., &amp; Sharma, M (2023). Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs. <i>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</i> 76(1) 165–171. DOI:<a href=\"https://doi.org/10.1093/cid/ciac180\">10.1093/cid/ciac180</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35245942/\">https://pubmed.ncbi.nlm.nih.gov/35245942</a></p></li><li><p>Bhardwaj, M, et al., &amp; Nandi, U (2023). Impact of Disease States on the Oral Pharmacokinetics of EIDD-1931 (an Active Form of Molnupiravir) in Rats for Implication in the Dose Adjustment. <i>Molecular pharmaceutics</i> 20(9) 4597–4610. DOI:<a href=\"https://doi.org/10.1021/acs.molpharmaceut.3c00314\">10.1021/acs.molpharmaceut.3c00314</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37527414/\">https://pubmed.ncbi.nlm.nih.gov/37527414</a></p></li><li><p>Carlin, AF, et al., &amp; Hostetler, KY (2024). Oral pharmacokinetics and efficacy of oral phospholipid remdesivir nucleoside prodrugs against SARS-CoV-2 in mice. <i>Antimicrobial agents and chemotherapy</i> 68(10) e0103924–None. DOI:<a href=\"https://doi.org/10.1128/aac.01039-24\">10.1128/aac.01039-24</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39240093/\">https://pubmed.ncbi.nlm.nih.gov/39240093</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Molnupiravir;
